RCG
NBIX icon

Ruggie Capital Group’s Neurocrine Biosciences NBIX Stock Holding History

Ruggie Capital Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-33
Closed -$2K – 282
2015
Q2 		$2K Hold
33
– – ﹤0.01% 282
2015
Q1 		$1K Buy
+33
New +$1.18K ﹤0.01% 261

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ruggie Capital Group's NBIX Position: Q3 2015 in Review

Ruggie Capital Group sold out of Neurocrine Biosciences (NBIX) in Q3 2015, closing a stake of 33 shares — an estimated $2K sold.

Ruggie Capital Group first reported a position in NBIX in Q1 2015 and held it in 2 quarters. The position peaked at $2K in Q2 2015. 207 funds tracked by Wall St. Rank hold NBIX as of Q3 2015.

  • Ruggie Capital Group reported no remaining Neurocrine Biosciences position as of Q3 2015 after selling out during the quarter.
  • Ruggie Capital Group sold 33 Neurocrine Biosciences shares in Q3 2015, an estimated $2K.
  • Ruggie Capital Group first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 2 quarters.
  • Ruggie Capital Group's Neurocrine Biosciences position peaked at $2K in Q2 2015.
  • 207 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2015.

Based on Ruggie Capital Group's 13F filing for Q3 2015, filed 12 Nov 2015.